Notizie
New data on Helsinn’s oncology pipeline presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2022
Conferenza stampa Farma Industria Ticino – 30 maggio 2022
Healiva® acquisisce da Smith+Nephew due asset di terapia cellulare per la guarigione delle ferite
Helsinn Establishes New R&D Hub in the U.S. to Support its Global Fully Integrated Targeted Therapy (FITT) Strategy
Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer
Helsinn to present data at upcoming AMMF’s 2022 European Cholangiocarcinoma Conference
Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi®
United States Ambassador Scott Miller meets the Chairman of Farma Industria Ticino Association
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*
Progetto Talenti
Cultura e salute
Linkedin